Table of Contents

List of Tables

List of Figures

Report Guidance

GlobalData Clinical Trials Report Coverage

Clinical Trials by Region

Clinical Trials and Average Enrollment by Country

Top Five Countries Contributing to Clinical Trials in Asia-Pacific

Top Five Countries Contributing to Clinical Trials in Europe

Top Countries Contributing to Clinical Trials in North America

Top Countries Contributing to Clinical Trials in Middle East and Africa

Top Countries Contributing to Clinical Trials in Central and South America

Clinical Trials by G7 Countries: Proportion of Pancreatic Ductal Adenocarcinoma to Oncology Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of Pancreatic Ductal Adenocarcinoma to Oncology Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in Pancreatic Ductal Adenocarcinoma Therapeutics Clinical Trials

Prominent Drugs

Latest Clinical Trials News on Pancreatic Ductal Adenocarcinoma

Nov 06, 2019: Oncolytics Biotech announces publication of positive REO 024 study results for Pelareorep in combination with Keytruda in patients with Advanced Pancreatic Adenocarcinoma

Nov 05, 2019: Gritstone Oncology announces data on novel shared tumor-specific neoantigens identified by its EDGE platform and contained within its SLATE Immunotherapy

Oct 15, 2019: Oncolytics Biotech presents clinical data highlighting the effectiveness of intravenous delivery to and replication of Pelareorep in tumors

Clinical Trial Profile Snapshots

Appendix

Abbreviations

Definitions

Research Methodology

Secondary Research

About GlobalData

Contact Us

Disclaimer

Source

Pancreatic Ductal Adenocarcinoma Global Clinical Trials Review, H2, 2019

Summary

GlobalData's clinical trial report, “Pancreatic Ductal Adenocarcinoma Global Clinical Trials Review, H2, 2019" provides an overview of Treatment Pancreatic Ductal Adenocarcinoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Pancreatic Ductal Adenocarcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.